TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer –– Investigational New Drug (IND) application for TNG456, a ...

Q4 2024 Earnings Call Transcript March 5, 2025 Ocugen, Inc. reports earnings inline with expectations. Reported EPS is $-0.05 ...

Ocugen ( OCGN -3.41%) Q4 2024 Earnings Call Mar 05, 2025, 8:30 a.m. ET ...

Adds to Extensive Preclinical and Early Clinical Evidence that Nebokitug Interferes with Key Features of Systemic Sclerosis. TEL AVIV, Israel, (GLOBE NEWSWIRE) -- C ...

Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs extends cash ...

Scholar Rock Holding Corporation. ( NASDAQ: SRRK) Q4 2024 Earnings Conference Call February 27, 2025 8:15 AM ET Jay Backstrom - President & CEO Ted Myles - COO & CFO Tracey Sacco - Chief Commercial ...

Operator Good day, ladies and gentlemen, and welcome to the Exelixis fourth quarter and fiscal year 2024 financial results conference call. My name is Sherry, and I'll be your operator for today. As a ...

A new drug application is anticipated for 2029. The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has been cleared by the FDA ...

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic CAR T-cell therapy, paving the way for a phase 1 trial in lupus and other autoimmune diseases.

Kadimastem and iTolerance believe that the completion of the pre-IND meeting is a significant milestone toward the clinical ...